Willow vs Enhance MD: Oral GLP-1 tracking vs low-cost compounds
Willow vs Enhance MD centers on support and pricing. Quick verdict: choose Willow if you want a telehealth-first oral GLP-1 program built as a structured weight management journey with progress tracking and follow-up; choose Enhance MD if your priority is low first-month pricing and access to both semaglutide and tirzepatide with flat-rate ongoing pricing.
Explore Willow’s tracked program
Willow vs Enhance MD: core differences at a glance
This comparison uses only the supplied evidence. Both operate via licensed clinicians and require clinician review to determine medical appropriateness. Compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Most distinctive differences
- Price entry point: Willow starting price is 299 versus Enhance MD semaglutide from 49 first month and tirzepatide from 99 first month.
- Care model emphasis: Willow emphasizes progress tracking tools and follow-up consultations in a structured journey; Enhance MD emphasizes flat-rate pricing and multi-compound access.
- Compound options: Enhance MD offers both semaglutide and tirzepatide on one platform; Willow positions an oral GLP-1 program.
- Pricing structure: Enhance MD advertises flat-rate pricing that stays the same at every dose after the introductory period; Willow notes higher monthly entry pricing for some plans.
- Scale and volume evidence: Enhance MD reports more than 10,000 patients treated; no comparable volume capture was provided for Willow.
Direct comparison table
| Criteria | Willow | Enhance MD |
|---|---|---|
| Starting price | 299 | Semaglutide from 49 first month; Tirzepatide from 99 first month |
| Program focus | Oral GLP-1 with progress tracking and follow-up consultations | Clinician-directed metabolic programs with semaglutide and tirzepatide options |
| Pricing model | Higher monthly entry pricing for some plans reported | Flat-rate pricing: same price at every dose after introductory pricing |
| Compound options | Oral GLP-1 program highlighted | Both semaglutide and tirzepatide available |
| Support features | Licensed telehealth team, progress tracking tools, follow-up | Metabolic lab testing every 6 months; clinician-directed care |
| Regulatory note | Compounded medications, when offered, are not FDA-approved and are not reviewed by FDA | Compounded medications are not FDA-approved and are not reviewed by FDA |
Pricing and compound access
Enhance MD’s standout claim is semaglutide from 49 first month and tirzepatide from 99 first month as introductory offers. Enhance MD also emphasizes flat-rate pricing that stays the same at every dose, which means no fee escalation during titration according to the supplied evidence. Willow’s captured evidence lists a starting price of 299 and notes higher monthly entry pricing for some plans. Specific ongoing monthly fees for Willow were not supplied.
See Enhance MD introductory pricing
Care model and patient experience
Willow positions its oral GLP-1 program as a structured weight management journey rather than a medication subscription, emphasizing digital workflow, progress tracking, and follow-up consultations to convert GLP-1 efficacy into sustainable outcomes. Enhance MD positions clinician-directed metabolic care, offering both compounds on one platform and noting metabolic lab testing every 6 months in captured evidence. Enhance MD also reports treating more than 10,000 patients.
Compare Willow support features
Regulatory and medication notes
Both providers state that treatment is available only when a licensed clinician determines it is medically appropriate. Both sources include the regulatory caution that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Enhance MD explicitly notes its medications are compounded, not FDA-approved finished products. Willow also states that compounded medications, when offered, are not FDA-approved.
Final comparison and who should pick which
Willow vs Enhance MD is essentially a tradeoff between structured follow-up and upfront affordability. If structured digital follow-up, progress tracking tools, and a telehealth-first oral GLP-1 program matter most, Willow emphasizes that model. If lowest first-month cost for semaglutide or access to both semaglutide and tirzepatide with flat-rate pricing is the priority, Enhance MD is positioned around that offer.
Choose Willow if…
You want a telehealth-first oral GLP-1 program framed as a structured weight management journey with progress tracking tools and follow-up consultations, and you accept higher monthly entry pricing for those support features.
Choose Enhance MD if…
You want semaglutide from 49 first month or tirzepatide from 99 first month as low introductory pricing, access to both compounds on one platform, and flat-rate pricing that stays the same at every dose after the introductory period.
Primary keyword: Willow vs Enhance MD
Ready to Compare Telehealth Providers?
Explore leading providers — physician-supervised, all-inclusive pricing, and free home delivery.
Compare All Providers →